Analysis of the role of cabozantinib and the reasons why it has not entered the Chinese market

Cabozantinib is a multi-target tyrosine kinase inhibitor mainly used to treat a variety of advanced solid tumors, including renal cell carcinoma, hepatocellular carcinoma and medullary thyroid carcinoma. Its mechanism of action is to block the growth, angiogenesis and metastasis of tumor cells by inhibiting multiple targets, such as MET, VEGFR2, RET, etc. This multi-target effect allows cabozantinib to exhibit broad anti-tumor activity in clinical practice, which is especially important for patients who are ineffective or resistant to traditional treatments.

In the treatment of renal cell carcinoma, cabozantinib has been shown to significantly extend patients' progression-free survival (PFS) and overall survival (OS). For patients with hepatocellular carcinoma, cabozantinib also provides a new treatment option after failure of first-line treatment. In addition, in the treatment of medullary thyroid cancer, cabozantinib effectively controls tumor progression by inhibiting RET mutations. These clinical study data demonstrate that cabozantinib has important therapeutic value in a variety of refractory cancers.

However, although cabozantinib has been widely used internationally, its original drug has not yet entered the Chinese market. This is mainly related to the following factors: First, new drugs entering the Chinese market need to go through a strict drug registration and approval process, including the submission and review of clinical trial data, which usually takes a long time. Secondly, the market access of drugs is also affected by business strategies. Pharmaceutical companies need to evaluate the demand, competitive environment and potential economic returns in the Chinese market. Finally, medical insurance policies and drug pricing mechanisms are also important factors affecting the entry of drugs into the Chinese market.

For Chinese patients, the lack of cabozantinib on the market does bring certain medication difficulties. Currently, patients can only purchase through overseas channels, which not only increases the financial burden, but may also face drug quality and transportation risks. However, with the optimization of domestic pharmaceutical policies and the development of generic drugs, cabozantinib is expected to be launched in the Chinese market in the future, providing treatment options for more patients.

Reference:https://en.wikipedia.org/wiki/Cabozantinib